. Author manuscript; available in PMC: 2011 Nov 1.

Published in final edited form as: Stem Cell Res. 2010 Aug 6;5(3):212–225. doi: 10.1016/j.scr.2010.07.003

Table 2B. Treatment of immunosuppressive antibodies to NOD/SCID mice does not influence engraftment of MCL tumor cells.

CD122 antibody (200 μg) was administrated by intraperitoneal injection on the day before transplantation. MCL tumor cells incubated with anti-CD19 or isotype control were injected into anti-CD122-treated NOD/SCID mice. Both populations formed MCL-like tumors in all mice tested.

Cells injected	Cell dose	# of mice tested	Total # of mice have tumors
MCL tumor cells (pt1, pt3) + anti-CD19 antibodies Injected into anti-CD122 treated NOD/SCID mice	5×10⁶	5	5/5 (100%)
MCL tumor cells(pt1, pt3) + IgG antibodies Injected to anti-CD122-NOD/SCID mice	5×10⁶	2	2/2(100%)